Hypertension occurs in 17–45 % of TKI-treated patients (40 % pazopanib, 30 % sunitinib, 4–11 % sorafenib) and bevacizumab (3–11 %) patients[10], but is rarely described with mTOR inhibitors[11]. Here, MTOR is linked to Hypertension.